Perrigo Company plc (PRGO) to Issue Quarterly Dividend of $0.29 on June 16th

Perrigo Company plc (NYSE:PRGO) announced a quarterly dividend on Wednesday, April 29th. Investors of record on Friday, May 29th will be given a dividend of 0.29 per share on Tuesday, June 16th. This represents a c) dividend on an annualized basis and a yield of 10.7%. The ex-dividend date is Friday, May 29th.

Perrigo has raised its dividend by an average of 0.1%per year over the last three years and has raised its dividend annually for the last 23 consecutive years. Perrigo has a dividend payout ratio of 35.5% meaning its dividend is sufficiently covered by earnings. Equities analysts expect Perrigo to earn $2.40 per share next year, which means the company should continue to be able to cover its $1.16 annual dividend with an expected future payout ratio of 48.3%.

Perrigo Trading Down 3.7%

PRGO stock opened at $10.80 on Wednesday. The business has a fifty day moving average price of $10.89 and a 200 day moving average price of $12.69. Perrigo has a fifty-two week low of $9.23 and a fifty-two week high of $28.43. The stock has a market capitalization of $1.49 billion, a price-to-earnings ratio of -0.82, a P/E/G ratio of 1.31 and a beta of 0.52. The company has a debt-to-equity ratio of 1.45, a current ratio of 2.72 and a quick ratio of 1.59.

Perrigo (NYSE:PRGO) last released its quarterly earnings results on Wednesday, May 6th. The company reported $0.43 earnings per share for the quarter, beating analysts’ consensus estimates of $0.39 by $0.04. Perrigo had a positive return on equity of 9.96% and a negative net margin of 43.50%.The firm had revenue of $841.80 million during the quarter, compared to analysts’ expectations of $1.04 billion. During the same period last year, the firm posted $0.60 EPS. The business’s revenue was down 7.2% on a year-over-year basis. Perrigo has set its FY 2026 guidance at 2.250-2.550 EPS. Analysts expect that Perrigo will post 2.14 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Bahl & Gaynor Inc. boosted its position in shares of Perrigo by 5.4% in the 3rd quarter. Bahl & Gaynor Inc. now owns 2,087,075 shares of the company’s stock worth $46,479,000 after purchasing an additional 107,774 shares during the last quarter. SG Americas Securities LLC boosted its position in shares of Perrigo by 1,495.6% in the 4th quarter. SG Americas Securities LLC now owns 134,433 shares of the company’s stock worth $1,871,000 after purchasing an additional 126,008 shares during the last quarter. Diamond Hill Capital Management Inc. boosted its position in shares of Perrigo by 8.6% in the 3rd quarter. Diamond Hill Capital Management Inc. now owns 1,797,746 shares of the company’s stock worth $40,036,000 after purchasing an additional 142,363 shares during the last quarter. Nicola Wealth Management LTD. boosted its position in shares of Perrigo by 38.4% in the 3rd quarter. Nicola Wealth Management LTD. now owns 281,000 shares of the company’s stock worth $6,257,000 after purchasing an additional 78,000 shares during the last quarter. Finally, Vanguard Group Inc. boosted its position in shares of Perrigo by 7.9% in the 4th quarter. Vanguard Group Inc. now owns 14,983,369 shares of the company’s stock worth $208,568,000 after purchasing an additional 1,101,154 shares during the last quarter. 95.91% of the stock is currently owned by institutional investors.

About Perrigo

Perrigo Company plc is a global healthcare supplier specializing in over-the-counter (OTC) and self-care products, as well as generic prescription pharmaceuticals and active pharmaceutical ingredients. The company develops, manufactures and distributes a broad array of consumer health products, including analgesics, vitamins and supplements, digestive health remedies, topical treatments, and infant formulas. Perrigo’s focus on private-label solutions has made it a leading partner for retailers and pharmacy chains seeking high-quality, value-oriented alternatives to branded medications and health supplements.

Organized across three principal business segments—Consumer Healthcare, Prescription Pharmaceuticals and Active Pharmaceutical Ingredients—Perrigo’s operations span research and development, manufacturing, quality assurance and global distribution.